Serum HMGB1 Levels Reflect Clinical Features of HLH
|
By LabMedica International staff writers Posted on 17 Sep 2019 |
|
Image: The High Mobility Group Box protein 1 (HMGB1) quantitative enzyme-linked immunosorbent assay kit (Photo courtesy of Shino-Test Corporation).
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome. Hypercytokinemia secreted from dysregulated hyperactivated monocytes, macrophages, T cells and NK cells has been reported to play a major role in HLH.
High mobility group box protein 1 (HMGB1) is a nonhistone nuclear protein that has a dual function. Inside the cell, HMGB1 binds DNA, regulating transcription and determining chromosomal architecture. HMGB1 can be released actively from innate immune cells in response to pathogenic products and passively from injured or dying cells.
Scientists at the Wakayama Medical University (Wakayama City, Japan) measured serum HMGB1 levels in 28 patients with HLH and six normal controls using a quantitative immunoassay. The patients were 21 boys and seven girls, aged from 10 days to 21 years, with a median age of 8.5 years. The underlying conditions of HLH were infection-associated HLH in 18 patients, malignancy-associated HLH in seven patients, and genetic HLH in three patients. The relations between serum HMGB1 levels and clinical symptoms and laboratory parameters were analyzed.
Blood samples were collected from the patients at the time of diagnosis of HLH and before specific treatment for HLH. Serial serum HMGB1 levels were measured in one patient. Whole blood collected in non-heparinized tubes was left to clot at room temperature for 30 minutes before centrifugation at 3,000 rpm for 15 minutes. The serum fractions were stored at −80 °C until the time of assay. Serum HMGB1 concentrations were determined using a quantitative enzyme-linked immunosorbent assay.
The scientists reported that serum HMGB1 levels were significantly higher in patients with HLH than in normal controls (median, 6.5 ng/mL). The serial serum HMGB1 levels in one patient fell to reflect the disease activity. Serum HMGB1 levels were significantly higher in patients with disseminated intravascular coagulation (DIC) than in patients without DIC and were also significantly higher in patients with central nervous system (CNS) complications than in patients without CNS complications. Serum HMGB1 levels were positively correlated with aspartate aminotransferase and negatively correlated with fibrinogen and hemoglobin.
The authors concluded that their study showed that serum HMGB1 levels reflect clinical features of childhood HLH. HMGB1 is a potential mediator involved in the pathogenesis and determining the clinical findings of HLH. The study was published on August 27, 2019, in the Journal of Blood Medicine.
Related Links:
Wakayama Medical University
 (3) (1).png)
High mobility group box protein 1 (HMGB1) is a nonhistone nuclear protein that has a dual function. Inside the cell, HMGB1 binds DNA, regulating transcription and determining chromosomal architecture. HMGB1 can be released actively from innate immune cells in response to pathogenic products and passively from injured or dying cells.
Scientists at the Wakayama Medical University (Wakayama City, Japan) measured serum HMGB1 levels in 28 patients with HLH and six normal controls using a quantitative immunoassay. The patients were 21 boys and seven girls, aged from 10 days to 21 years, with a median age of 8.5 years. The underlying conditions of HLH were infection-associated HLH in 18 patients, malignancy-associated HLH in seven patients, and genetic HLH in three patients. The relations between serum HMGB1 levels and clinical symptoms and laboratory parameters were analyzed.
Blood samples were collected from the patients at the time of diagnosis of HLH and before specific treatment for HLH. Serial serum HMGB1 levels were measured in one patient. Whole blood collected in non-heparinized tubes was left to clot at room temperature for 30 minutes before centrifugation at 3,000 rpm for 15 minutes. The serum fractions were stored at −80 °C until the time of assay. Serum HMGB1 concentrations were determined using a quantitative enzyme-linked immunosorbent assay.
The scientists reported that serum HMGB1 levels were significantly higher in patients with HLH than in normal controls (median, 6.5 ng/mL). The serial serum HMGB1 levels in one patient fell to reflect the disease activity. Serum HMGB1 levels were significantly higher in patients with disseminated intravascular coagulation (DIC) than in patients without DIC and were also significantly higher in patients with central nervous system (CNS) complications than in patients without CNS complications. Serum HMGB1 levels were positively correlated with aspartate aminotransferase and negatively correlated with fibrinogen and hemoglobin.
The authors concluded that their study showed that serum HMGB1 levels reflect clinical features of childhood HLH. HMGB1 is a potential mediator involved in the pathogenesis and determining the clinical findings of HLH. The study was published on August 27, 2019, in the Journal of Blood Medicine.
Related Links:
Wakayama Medical University
Gold Member
Hematology Analyzer
Medonic M32B
Pipette
Accumax Smart Series
Clinical Chemistry System
P780
Latest Clinical Chem. News
- VOCs Show Promise for Early Multi-Cancer Detection
- Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
- Gold Nanoparticles to Improve Accuracy of Ovarian Cancer Diagnosis
- Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy
- Simple Non-Invasive Hair-Based Test Could Speed ALS Diagnosis
- Paper Strip Saliva Test Detects Elevated Uric Acid Levels Without Blood Draws
- Prostate Cancer Markers Based on Chemical Make-Up of Calcifications to Speed Up Detection
- Breath Test Could Help Detect Blood Cancers
- ML-Powered Gas Sensors to Detect Pathogens and AMR at POC
- Saliva-Based Cancer Detection Technology Eliminates Need for Complex Sample Preparation
- Skin Swabs Could Detect Parkinson’s Years Before Symptoms Appear
- New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs
- New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
- Pen-Like Tool Quickly and Non-Invasively Detects Opioids from Skin
- Simple Urine Test Could Detect Multiple Cancers at Early Stage
- Earwax Test Accurately Detects Parkinson’s by Identifying Odor Molecules
Channels
Clinical Chemistry
view channel
VOCs Show Promise for Early Multi-Cancer Detection
Early cancer detection is critical to improving survival rates, but most current screening methods focus on individual cancer types and often involve invasive procedures. This makes it difficult to identify... Read more
Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
Kidney disease is typically diagnosed through blood or urine tests, often when patients present with symptoms such as blood in urine, shortness of breath, or weight loss. While these tests are common,... Read more
Molecular Diagnostics
view channel
New Diagnostic Marker for Ovarian Cancer to Enable Early Disease Detection
Ovarian cancer remains the deadliest gynecological malignancy worldwide, responsible for more than 200,000 deaths annually. Unlike other cancers, ovarian cancer still lacks a reliable screening test.... Read more
Urine Test Detects Early Stage Pancreatic Cancer
Pancreatic cancer remains among the hardest cancers to detect early. In the UK, around 10,000 people are diagnosed each year, but only 5% survive beyond five years. Late diagnosis is a major factor—more... Read more
Immunology
view channel
Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
Immunotherapy has revolutionized cancer care by harnessing the immune system to fight tumors, yet predicting who will benefit remains a major challenge. Many patients undergo costly and taxing treatment... Read more
Signature Genes Predict T-Cell Expansion in Cancer Immunotherapy
Modern cancer immunotherapies rely on the ability of CD8⁺ T cells to rapidly multiply within tumors, generating the immune force needed to eliminate cancer cells. However, the biological triggers behind... Read more
Microbiology
view channel
High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample
Gastrointestinal (GI) infections are among the most common causes of illness worldwide, leading to over 1.7 million deaths annually and placing a heavy burden on healthcare systems. Conventional diagnostic... Read more
Fast Noninvasive Bedside Test Uses Sugar Fingerprint to Detect Fungal Infections
Candida bloodstream infections are a growing global health threat, causing an estimated 6 million cases and 3.8 million deaths annually. Hospitals are particularly vulnerable, as weakened patients after... Read more
Pathology
view channel
New Molecular Analysis Tool to Improve Disease Diagnosis
Accurately distinguishing between similar biomolecules such as proteins is vital for biomedical research and diagnostics, yet existing analytical tools often fail to detect subtle structural or compositional... Read more
Tears Offer Noninvasive Alternative for Diagnosing Neurodegenerative Diseases
Diagnosing and monitoring eye and neurodegenerative diseases often requires invasive procedures to access ocular fluids. Ocular fluids like aqueous humor and vitreous humor contain valuable molecular information... Read more
Technology
view channel
Cell-Sorting Device Uses Electromagnetic Levitation to Precisely Direct Cell Movement
Sorting different cell types—such as cancerous versus healthy or live versus dead cells—is a critical task in biology and medicine. However, conventional methods often require labeling, chemical exposure,... Read more
Embedded GPU Platform Enables Rapid Blood Profiling for POC Diagnostics
Blood tests remain a cornerstone of medical diagnostics, but traditional imaging and analysis methods can be slow, costly, and reliant on dyes or contrast agents. Now, scientists have developed a real-time,... Read more
Industry
view channel
Qiagen Acquires Single-Cell Omics Firm Parse Biosciences
QIAGEN (Venlo, Netherlands) has entered into a definitive agreement to fully acquire Parse Biosciences (Seattle, WA, USA), a provider of scalable, instrument-free solutions for single-cell research.... Read more
Puritan Medical Products Showcasing Innovation at AMP2025 in Boston
Puritan Medical Products (Guilford, ME, USA), the world’s most trusted manufacturer of swabs and specimen collection devices, is set to exhibit at AMP2025 in Boston, Massachusetts, from November 11–15.... Read more
Advanced Instruments Merged Under Nova Biomedical Name
Advanced Instruments (Norwood, MA, USA) and Nova Biomedical (Waltham, MA, USA) are now officially doing business under a single, unified brand. This transformation is expected to deliver greater value... Read more
